NUCIEN PHARMA(SH:688189) IPO日报·2025-08-27 05:49Core Viewpoint - The article discusses the significant asset restructuring of Hunan Nanxin Pharmaceutical Co., Ltd., which aims to enhance its product pipeline and improve financial performance following a period of continuous losses [2][5][7]. Group 1: Company Overview - Hunan Nanxin Pharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of antiviral and infectious disease treatment drugs, as well as medications for major diseases like cancer and diabetes [5]. - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 26, 2020 [5]. Group 2: Financial Performance - In 2021, the company reported a revenue of 685 million yuan, a decrease of 37.08% year-on-year, and a net loss of 167 million yuan, a decline of 225.50% compared to the previous year [5]. - The company has faced continuous losses since 2021, with a projected loss of 397 million yuan in 2024, attributed to industry policy changes and intensified market competition [6]. Group 3: Asset Restructuring - On August 26, 2023, the company announced a cash acquisition of specific assets from Future Pharmaceutical for no more than 480 million yuan, which includes already marketed and in-development products [4][5]. - This acquisition is expected to enhance the company's product offerings and improve its revenue and profit potential, particularly through established sales channels and academic promotion systems [7].